Can Therapy of Hepatitis C Affect the Development of Hepatocellular Carcinoma?

Author: Laura M. Kulik MD1
View More View Less
  • 1 From the Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Chronic inflammation induced by viral infections and their role in carcinogenesis is well recognized. Two hepatotropic viruses, hepatitis B and hepatitis C (HCV), have been linked worldwide to the development of hepatocellular carcinoma (HCC). Although orthotopic liver transplant offers the best chance for cure and long-term survival, the demand for organs far outweighs the supply. The incidence of HCC in the United States has increased over the past 3 decades. HCV-induced cirrhosis is believed to play a significant role in the rising rate of HCC. Therefore, primary measures to prevent HCC in HCV-infected patients are urgently needed. Numerous studies of the HCV HCC patient have considered primary treatment with interferon-based therapy. However, secondary prevention currently seems to carry more promise. This article evaluates and assesses various treatments for primary and secondary chemoprevention in the setting of HCV.

Correspondence: Laura M. Kulik, MD, Assistant Professor, Feinberg School of Medicine, Northwestern University, 675 North St. Clair Street, Suite 15-250, Chicago, IL 60611. E-mail: LKulik@nmff.org
  • 1.

    Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860867.

  • 2.

    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:19071917.

  • 3.

    Bosch FX, Ribes J, Diaz M et al.. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5S16.

  • 4.

    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745750.

  • 5.

    Lin S, Chu C. Secondary prevention of hepatitis c virus-related hepatocellular carcinoma [editorial]. J Gastroenterol Hepatol 2005;20:14751477.

    • Search Google Scholar
    • Export Citation
  • 6.

    Yao FY, Bass NM, Nikolai B et al.. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003;9:684692.

    • Search Google Scholar
    • Export Citation
  • 7.

    United Network for Organ Sharing (UNOS) Web site. Available at: http://www.UNOS.org. Accessed April 26, 2006.

  • 8.

    Davis GL. Chronic hepatitis C and liver transplantation. Rev Gastroenterol Disord 2004;4:717.

  • 9.

    Chen CJ, Yang HI, Su J et al.. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. REVEAL-HBV Study Group. JAMA 2006;295:6573.

    • Search Google Scholar
    • Export Citation
  • 10.

    Fattovich G. Progression of hepatitis B and C to hepatocellular carcinoma in western countries. Hepatogastroenterology 1998;45:12061213.

    • Search Google Scholar
    • Export Citation
  • 11.

    De Mitri MS, Poussin K, Baccarini P et al.. HCV-associated liver cancer without cirrhosis. Lancet 1995;345:413415.

  • 12.

    Bralet MP, Regimbeau JM, Pineau P et al.. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000;32:200204.

    • Search Google Scholar
    • Export Citation
  • 13.

    Lee JS, Chu IS, Heo J et al.. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667676.

    • Search Google Scholar
    • Export Citation
  • 14.

    Niederau C, Lange S, Heintges T et al.. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:16871695.

    • Search Google Scholar
    • Export Citation
  • 15.

    Yoshida H, Shiratori Y, Moriyama M et al.. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174181.

    • Search Google Scholar
    • Export Citation
  • 16.

    Benvegnu L, Alberti A. Risk factors and prevention of hepatocellular carcinoma in HCV infection. Digest Dis Sci 1996;41;49S55S.

  • 17.

    Yano H, Iemura A, Haramaki M et al.. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999;29:17081717.

    • Search Google Scholar
    • Export Citation
  • 18.

    Fattovich G, Stroffolini T, Zagni I et al.. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(suppl 1):3550.

    • Search Google Scholar
    • Export Citation
  • 19.

    McHutchison JG, Manns M, Patel K et al.. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:10611069.

    • Search Google Scholar
    • Export Citation
  • 20.

    Manns MP, McHutchison JG, Gordon SC et al.. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958965.

    • Search Google Scholar
    • Export Citation
  • 21.

    Hadziyannis SJ, Sette H Jr, Morgan TR et al.. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346355.

    • Search Google Scholar
    • Export Citation
  • 22.

    Manns MP, McHutchison JG, Gordon SC et al.. Peginterferon alfa-2b plus ribavirin compared with interferon alpa-2b plus ribavirin for the initial treatment of chronic hepatitis C: a randomized trial. Lancet 2003;358:958965.

    • Search Google Scholar
    • Export Citation
  • 23.

    Fried MW, Shiffman ML, Reddy R et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 2002;347:975982.

  • 24.

    Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939945. Erratum in Nature 2005; 437:290.

  • 25.

    Nishiguchi S, Kuroki T, Nakatani S et al.. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:10511055.

    • Search Google Scholar
    • Export Citation
  • 26.

    Azzaroli F, Accogli E, Nigro G et al.. Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World J Gastroenterol 2004;10:30993102.

    • Search Google Scholar
    • Export Citation
  • 27.

    Valla DC, Chevallier M, Marcellin P et al.. Treatment of hepatitis c virus-related cirrhosis: a randomized, control of interferon alfa-2b versus no treatment. Hepatology 1999;29:18701875.

    • Search Google Scholar
    • Export Citation
  • 28.

    Bernardinello E, Cavalletto L, Chemello L et al.. Long-term clinical outcome after beta-interferon therapy in patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology 1999;46:32163222.

    • Search Google Scholar
    • Export Citation
  • 29.

    Okanoue T, Itaoh Y, Minami M et al.. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999;30:653659.

    • Search Google Scholar
    • Export Citation
  • 30.

    Imai Y, Kawata S, Tamura S et al.. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:9499.

    • Search Google Scholar
    • Export Citation
  • 31.

    Camma C, Di Bona D, Craxi A. The impact of antiviral treatments on the course of chronic hepatitis c: an evidence-based approach. Curr Pharm Des 2004;10:21232130.

    • Search Google Scholar
    • Export Citation
  • 32.

    Baffis V, Shrier I, Sherker AH et al.. Use of interferon for prevention of hepatocellular cancer in cirrhotic patients with hepatitis B or hepatitis C infection. Ann Internal Med 1999;131:696701.

    • Search Google Scholar
    • Export Citation
  • 33.

    Papatheodorisdis GV, Papadimitropoulos VC, Hadziyannis SJ. Effects of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001;15:689698.

    • Search Google Scholar
    • Export Citation
  • 34.

    Shiratori Y, Ito Y, Yokosuka O et al.. Tokyo-Chiba Hepatitis Research Group. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105114.

    • Search Google Scholar
    • Export Citation
  • 35.

    Shiratori Y, Yokosuka O, Nakata R et al.. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Hepatology 1999;29:15731580.

    • Search Google Scholar
    • Export Citation
  • 36.

    Shiratori Y, Moriyama M, Imazeki F et al.. A prospective study of interferon therapy modified by pre-treatment viral load in cirrhotic patients. Tokyo-Chiba Hepatitis Research Group. Liver 2000;20:271280.

    • Search Google Scholar
    • Export Citation
  • 37.

    Yoshida H, Arakawa Y, Sata M et al.. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123:483491.

    • Search Google Scholar
    • Export Citation
  • 38.

    Bruix J, Sherman M. Management of hepatocellular carcinoma. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Hepatology 2005;42:12081236.

    • Search Google Scholar
    • Export Citation
  • 39.

    Ikeda K, Saitoh S, Koida I et al.. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:4753.

    • Search Google Scholar
    • Export Citation
  • 40.

    Tsukuma H, Hiyama T, Tanaka S et al.. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:17971801.

    • Search Google Scholar
    • Export Citation
  • 41.

    Murashima S, Tanaka M, Haramaki M et al.. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig Dis Sci 2006;51:808812.

    • Search Google Scholar
    • Export Citation
  • 42.

    Di Bisceglie AM, Sterling RK, Chung RT et al.. HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Study. J Hepatol 2005;43:434441.

    • Search Google Scholar
    • Export Citation
  • 43.

    Saito Y, Saito H, Tada S et al.. Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis. Hepatogastroenterology 2005;52:14911496.

    • Search Google Scholar
    • Export Citation
  • 44.

    Afdhal N, Freilich B, Levine R et al.. Colchicine versus peg-interferon long term (COPILOT) trial: interim analysis of clinical outcomes at year 2. Hepatology 2004;40:238A. Abstract.

    • Search Google Scholar
    • Export Citation
  • 45.

    Ikeda K, Arase Y, Saitoh S et al.. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor- a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228032. Abstract.

    • Search Google Scholar
    • Export Citation
  • 46.

    Suou T, Mitsuda A, Koda M et al.. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res 2001;20:301311.

    • Search Google Scholar
    • Export Citation
  • 47.

    Kubo S, Nishiguchi S, Hirohashi K et al.. Clinical significance of interferon therapy in treatments for hepatitis C virus-related hepatocellular carcinoma [Japanese]. Gan To Kagaku Ryoho 2001;28:19751979.

    • Search Google Scholar
    • Export Citation
  • 48.

    Miyaguchi S, Watanabe T, Takahashi H et al.. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepatogastroenterology 2002;49:724729.

    • Search Google Scholar
    • Export Citation
  • 49.

    Shiratori Y, Shiina S, Teratani T et al.. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299306.

    • Search Google Scholar
    • Export Citation
  • 50.

    Lin SM, Lin CJ, Hsu CW et al.. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004;100:376382.

    • Search Google Scholar
    • Export Citation
  • 51.

    Bruix J. Hepatocellular Carcinoma. Barcelona, Spain: Mallorca; 2004.

  • 52.

    Hung CH, Lee CM, Wang JH et al.. Antiviral therapy after nonsurgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 2005;20:15531559.

    • Search Google Scholar
    • Export Citation
  • 53.

    Gane EJ, Portmann BC, Naoumov NV et al.. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815820.

  • 54.

    Everson GT, Trotter J, Forman L et al.. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255262.

    • Search Google Scholar
    • Export Citation
  • 55.

    National Institutes of Health. LADR protocol—a substudy of the Adult-to-Adult Living Donor Liver Transplant Cohort Protocol (A2ALL). Available at: http://www.nih-a2all.com. Accessed April 26, 2006.

    • Search Google Scholar
    • Export Citation
  • 56.

    Ikeda M, Fujiyama S, Tanaka M et al.. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. Gastroenterol 2005;40:148156.

    • Search Google Scholar
    • Export Citation
  • 57.

    Makiyama A, Itoh Y, Kasahara A et al.. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004;101:16161622.

    • Search Google Scholar
    • Export Citation
  • 58.

    Toyoda H, Kumada T, Hayashi K et al.. Characteristics and prognosis of hepatocellular carcinoma detected in sustained responders to interferon therapy for chronic hepatitis C. Yon-Ken HCV-HCC Follow-up Study Group. Cancer Detect Prev 2003;27:498502.

    • Search Google Scholar
    • Export Citation
  • 59.

    Ikeda K, Kobayashi M, Saitoh S et al.. Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients. Oncology 2003;65:204210.

    • Search Google Scholar
    • Export Citation
  • 60.

    Kensler TW, Egner PA, Wang JB et al.. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterol 2004;127(suppl 1):S310S318.

    • Search Google Scholar
    • Export Citation
  • 61.

    Koga H. Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors? Cancer 2003;98:661667.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 69 28 4
PDF Downloads 37 11 2
EPUB Downloads 0 0 0